Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Apellis Pharmaceuticals Inc 100 FIFTH AVENUE WALTHAM MA 02451 USA

www.apellis.com Employees: 710 P: 617-977-5700

Sector:

Medical

Description:

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

Key Statistics

Overview:

Market Capitalization, $K 2,522,909
Enterprise Value, $K 2,469,789
Shares Outstanding, K 126,525
Float, K 118,301
% Float 93.50%
Short Interest, K 16,121
Short Float 12.74%
Days to Cover 7.29
Short Volume Ratio 0.70
% of Insider Shareholders 6.50%
% of Institutional Shareholders 96.29%

Financials:

Annual Sales, $ 781,370 K
Annual Net Income, $ -197,880 K
Last Quarter Sales, $ 458,580 K
Last Quarter Net Income, $ 215,720 K
EBIT, $ 80,390 K
EBITDA, $ 92,680 K

Growth:

1-Year Return -32.93%
3-Year Return -61.69%
5-Year Return -56.35%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 65.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.67 on 10/30/25
Next Earnings Date 02/27/26
Earnings Per Share ttm 0.31
EPS Growth vs. Prev Qtr 606.06%
EPS Growth vs. Prev Year 463.04%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

APLS Ratios

Ratio
Price/Earnings ttm 66.23
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 18.94%
Return-on-Assets % 5.04%
Profit Margin % -25.32%
Debt/Equity 1.13
Price/Sales 2.52
Price/Cash Flow N/A
Price/Book 6.47
Book Value/Share 3.17
Interest Coverage -3.87
60-Month Beta 0.31
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar